News
Media
Medical World NewsPodcastsVideosInsightsPeer ExchangeMedia DayNews NetworkRoundtables
Conference
Conference CoverageConference Listing
Publication
More
CME/CE
Partners
Resources
Interactive ToolsSpecial ProjectsSponsored
Contribute
Case StudiesWriters and Mentors

Subscribe

  • News
  • Media
  • Conference
  • Publication
  • CME/CE
  • Partners
  • Resources
  • Contribute
  • Subscribe
  • Antimicrobial Stewardship
  • Blood-Borne Diseases
    • Ebola
    • HCV / Hepatitis
  • Coronavirus / COVID
  • Food Borne Infection / Food Safety
    • E. Coli
    • Food Safety
    • Listeria
    • Salmonella
  • Fungal Infections
    • Candida auris
  • Gastrointestinal Infections
    • C. Difficile
    • H. Pylori
    • Norovirus
  • Healthcare Associated Infections (HAI)
  • Prevention
    • Antibiotics
    • Immunizations
    • Vaccines
  • Respiratory Infections
    • Community-Acquired Pneumonia
    • Measles
    • Influenza
  • Sexually Transmitted Diseases
    • HIV / AIDS
    • HPV
    • HSV
    • PrEP
  • Skin & Soft Tissue Diseases
    • MRSA
  • Zoonotic & Vector-Borne Diseases
    • Lyme Disease
    • ZIKA
Spotlight -
Antimicrobial Stewardship|
Bench to Bedside With SIDP|
C. difficile |
Clinical Corner|
Fungal Infections|
Hepatitis|
RSV: A New Era in Prevention
Advertisement

Aislinn Antrim

Advertisement

Articles by Aislinn Antrim

Texas Could Be Site of Next Large Measles Outbreak, Study Predicts

ByAislinn Antrim
August 28th 2019

Texas could be the site of the next large measles outbreak in the United States, according to a new study that highlights the low vaccination rates among schools there.

Advertisement

Latest Updated Articles

  • Texas Could Be Site of Next Large Measles Outbreak, Study Predicts
    Texas Could Be Site of Next Large Measles Outbreak, Study Predicts

    Published: August 28th 2019 | Updated:



Advertisement
Advertisement

Trending on Contagion Live

1

Developing a COVID-19 Vaccine Alternative

2

New Data Highlight Adult Pneumococcal Serotypes with Greater Antibiotic Resistance and Disease Burden Covered by Merck’s Vaccine

3

Generic Lenacapavir Could Cost as Little as $25 Per Person Annually

4

Building Trust Through Vaccine Education and Science Communication

5

Real-World Data Reinforce Effectiveness and Safety of Fecal Microbiota Therapy for Preventing Recurrent C difficile

  • About Us
  • Advertise
  • Editorial
  • Contact Us
  • Do Not Sell My Information
  • Privacy
  • Terms & Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us